News | Oncology Diagnostics | January 31, 2018

Elekta and IBM Watson Health Bringing Artificial Intelligence to Oncology

Elekta to sell Watson for Oncology clinical decision support paired within Mosaiq OIS and other Elekta solutions

Elekta and IBM Watson Health Bringing Artificial Intelligence to Oncology

January 31, 2018 – Elekta announced it is collaborating with IBM Watson Health to offer Watson for Oncology with Elekta’s cancer care solutions. Under the terms of a new agreement, Elekta will sell Watson for Oncology beginning in early 2018 as a clinical decision support (CDS) solution paired within Elekta’s digital cancer care solutions, including the Mosaiq oncology information system (OIS). Elekta intends to offer both solutions in most markets around the world including the U.S., Brazil, certain major European and Asian markets, as well as India and Australia.

Cancer is responsible for one in six deaths around the world, and each year there are more than 14 million new cancer cases worldwide.(1) As healthcare providers and systems seek to enable data-driven, evidence-based cancer care, an explosion of medical information has created both challenges and opportunities to help improve quality of care. Currently, approximately 50,000 oncology research papers are published annually,(2) and by 2020 medical information is projected to double every 73 days(3), outpacing the ability of humans to keep up with the proliferation of medical knowledge.

Elekta CEO Richard Hausmann said the goal of the collaboration is to bring cutting-edge artificial intelligence (AI) technology to the cancer care continuum, including treatment planning, enabling evidence-based treatment recommendations for every patient regardless of where they are treated.

Watson for Oncology was developed by IBM in collaboration with Memorial Sloan Kettering Cancer Center (MSK) in New York. It can summarize key medical attributes of a patient, and provide information to oncologists to help them deliver treatment options based on training from MSK oncologists. Watson for Oncology ranks the treatment options, linking to peer-reviewed studies that have been curated by MSK. Watson for Oncology also provides a large corpus of medical literature for a physician to consider, drawing on more than 300 medical journals, more than 200 textbooks, and nearly 15 million pages of text to provide insights about different treatment options.

For more information: www.elekta.com, www.ibm.com/watson/health

References:

(1) World Health Organization, Cancer Fact Sheet:  http://www.who.int/mediacentre/factsheets/fs297/en/

(2) PubMed, accessed at pubmed.com

(3) Densen, Peter, Challenges and Opportunities Facing Medical Education 2011. Transactions in the American Clinical and Climatological Association. Accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116346/

Related Content

AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s flagship image analysis platform.
News | Artificial Intelligence | January 18, 2021
January 18, 2021 — AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient ca
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
News | Artificial Intelligence | January 12, 2021
January 12, 2021 — The U.S.
Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site. #AI #AIhealthcare #AIecho

Ultromics will offer its artificial intelligence driven EchoGo Pro as a stress-echo module in the EchoGo suite alongside EchoGo Core, its AI solution for automated systolic function and strain analysis. The EchoGo suite is a cloud-based service that uses artificial intelligence to fully automate the pathway to diagnosis, providing near-instant reports for clinicians without any need for physical software on site.

News | Artificial Intelligence | January 06, 2021
January 6, 2021 — The U.S.
Volpara Health announced two new research studies using AI-powered software to score breast density objectively and consistently to evaluate its impact in mammography and breast cancer risk assessment.
News | Breast Density | December 30, 2020
December 30, 2020 — Volpara Health announced two new research studies using...
 EvoHealth, a trailblazer in incorporating new technology in healthcare IT software, announced it has exceeded its first milestone of more than 100 customers with over 200 locations.
News | Information Technology | December 22, 2020
December 22, 2020 — EvoHealth, a trailblazer in incorporating n
The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | December 17, 2020 | By Melinda Taschetta-Millane and Dave Fornell
Published in Nature Communications, ReceptorNet is a breakthrough deep-learning algorithm that can determine hormone-receptor status - a crucial biomarker for clinicians when deciding on the appropriate treatment path for breast cancer treatment
News | Artificial Intelligence | December 14, 2020
December 14, 2020 — Imagine being a doctor and having a precocious resident permanently by your side, giving you bril
Bayer Radiology is announcing Radimetrics v3.0, the newest evolution of its enterprise dose management application.
News | Radiation Dose Management | December 11, 2020
December 11, 2020 — Bayer Radiology is announcing Radimetrics v3.0, the newest evolution of its enterprise dose manag